Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.
Hyperglycemic conditions of diabetes accelerate protein modifications by glucose leading to the accumulation of advanced glycation end-products (AGEs). We have investigated the conversion of protein-Amadori intermediate to protein-AGE and the mechanism of its inhibition by pyridoxamine (PM), a potent AGE inhibitor that has been shown to prevent diabetic complications in animal models. During incubation of proteins with physiological diabetic concentrations of glucose, PM prevented the degradation of the protein glycation intermediate identified as fructosyllysine (Amadori) by 13C NMR using [2-13C]-enriched glucose. Subsequent removal of glucose and PM led to conversion of protein-Amadori to AGE Nepsilon-carboxymethyllysine (CML). We utilized this inhibition of post-Amadori reactions by PM to isolate protein-Amadori intermediate and to study the inhibitory effect of PM on its degradation to protein-CML. We first tested the hypothesis that PM blocks Amadori-to-CML conversion by interfering with the catalytic role of redox metal ions that are required for this glycoxidative reaction. Support for this hypothesis was obtained by examining structural analogs of PM in which its known bidentate metal ion binding sites were modified and by determining the effect of endogenous metal ions on PM inhibition. We also tested the alternative hypothesis that the inhibitory mechanism involves formation of covalent adducts between PM and protein-Amadori. However, our 13C NMR studies demonstrated that PM does not react with the Amadori. Because the mechanism of interference with redox metal catalysis is operative under the conditions closely mimicking the diabetic state, it may contribute significantly to PM efficacy in preventing diabetic complications in vivo. Inhibition of protein-Amadori degradation by PM also provides a simple procedure for the isolation of protein-Amadori intermediate, prepared at physiological levels of glucose for relevancy, to study both the biological effects and the chemistry of post-Amadori pathways of AGE formation.
Voziyan
Paul A
PA
Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN 37232, USA. paul.voziyan@vanderbilt.edu
Khalifah
Raja G
RG
Thibaudeau
Christophe
C
Yildiz
Alaattin
A
Jacob
Jaison
J
Serianni
Anthony S
AS
Hudson
Billy G
BG
D000818:Animals; D002247:Carbon Isotopes; D003920:Diabetes Mellitus / Q000378:metabolism; D005947:Glucose / Q000502:physiology*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000378:metabolism; D008670:Metals / Q000494:pharmacology; D019906:Nuclear Magnetic Resonance, Biomolecular; D010084:Oxidation-Reduction; D011499:Protein Processing, Post-Translational; D011506:Proteins / Q000378:metabolism; D011733:Pyridoxamine / Q000494:pharmacology
D002247:Carbon Isotopes; D017127:Glycation End Products, Advanced; D008670:Metals; D011506:Proteins; C033186:fructosyl-lysine; D011733:Pyridoxamine; C048496:N(6)-carboxymethyllysine; D005947:Glucose; D008239:Lysine